These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 17973947)

  • 1. Effect of progestins with different glucocorticoid activity on bone metabolism.
    Ishida Y; Mine T; Taguchi T
    Clin Endocrinol (Oxf); 2008 Mar; 68(3):423-8. PubMed ID: 17973947
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of combined risedronate and hormone replacement therapies on bone mineral density in postmenopausal women.
    Harris ST; Eriksen EF; Davidson M; Ettinger MP; Moffett AH; Baylink DJ; Crusan CE; Chines AA
    J Clin Endocrinol Metab; 2001 May; 86(5):1890-7. PubMed ID: 11344179
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized trial comparing hormone replacement therapy (HRT) and HRT plus calcitriol in the treatment of postmenopausal osteoporosis with vertebral fractures: benefit of the combination on total body and hip density.
    Gutteridge DH; Holzherr ML; Retallack RW; Price RI; Will RK; Dhaliwal SS; Faulkner DL; Stewart GO; Stuckey BG; Prince RL; Criddle RA; Drury PJ; Tran L; Bhagat CI; Kent GN; Jamrozik K
    Calcif Tissue Int; 2003 Jul; 73(1):33-43. PubMed ID: 14506952
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effects of progestins on bone density and bone metabolism in postmenopausal women: a randomized controlled trial.
    Liu JH; Muse KN
    Am J Obstet Gynecol; 2005 Apr; 192(4):1316-23; discussion 1323-4. PubMed ID: 15846228
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Postmenopausal femur bone loss: effects of a low dose hormone replacement therapy.
    Gambacciani M; Ciaponi M; Cappagli B; Monteleone P; Benussi C; Bevilacqua G; Genazzani AR
    Maturitas; 2003 Jul; 45(3):175-83. PubMed ID: 12818462
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized trial comparing low-dose hormone replacement therapy and HRT plus 1alpha-OH-vitamin D3 (alfacalcidol) for treatment of postmenopausal bone loss.
    Mizunuma H; Shiraki M; Shintani M; Gorai I; Makita K; Itoga S; Mochizuki Y; Mogi H; Iwaoki Y; Kosha S; Yasui T; Ishihara O; Kurabayashi T; Kasuga Y; Hayashi K
    J Bone Miner Metab; 2006; 24(1):11-5. PubMed ID: 16369892
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of different treatment modalities for postmenopausal patients with osteopenia: hormone replacement therapy, calcitonin and clodronate.
    Tiraş MB; Noyan V; Yildiz A; Biberoğlu K
    Climacteric; 2000 Jun; 3(2):92-101. PubMed ID: 11910657
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Short-term increases in bone turnover markers predict parathyroid hormone-induced spinal bone mineral density gains in postmenopausal women with glucocorticoid-induced osteoporosis.
    Lane NE; Sanchez S; Genant HK; Jenkins DK; Arnaud CD
    Osteoporos Int; 2000; 11(5):434-42. PubMed ID: 10912846
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sublingual administration of micronized estradiol and progesterone, with and without micronized testosterone: effect on biochemical markers of bone metabolism and bone mineral density.
    Miller BE; De Souza MJ; Slade K; Luciano AA
    Menopause; 2000; 7(5):318-26. PubMed ID: 10993031
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A four-year randomized controlled trial of hormone replacement and bisphosphonate, alone or in combination, in women with postmenopausal osteoporosis.
    Wimalawansa SJ
    Am J Med; 1998 Mar; 104(3):219-26. PubMed ID: 9552083
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Parathyroid hormone added to established hormone therapy: effects on vertebral fracture and maintenance of bone mass after parathyroid hormone withdrawal.
    Cosman F; Nieves J; Woelfert L; Formica C; Gordon S; Shen V; Lindsay R
    J Bone Miner Res; 2001 May; 16(5):925-31. PubMed ID: 11341338
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Peripheral quantitative computed tomography (pQCT) is useful for monitoring bone mineral density of the patients who receive hormone replacement therapy.
    Sawada K; Morishige K; Ohmichi M; Nishio Y; Yamamoto T; Hayakawa J; Mabuchi S; Isobe A; Sasaki H; Sakata M; Tasaka K; Murata Y
    Maturitas; 2007 Apr; 56(4):343-9. PubMed ID: 17010541
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of alendronate and hormone replacement therapy, alone or in combination, on bone mass in postmenopausal women with osteoporosis: a prospective, randomized study.
    Tiraş MB; Noyan V; Yildiz A; Yildirim M; Daya S
    Hum Reprod; 2000 Oct; 15(10):2087-92. PubMed ID: 11006178
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of teriparatide [rhPTH(1-34)] on BMD when given to postmenopausal women receiving hormone replacement therapy.
    Ste-Marie LG; Schwartz SL; Hossain A; Desaiah D; Gaich GA
    J Bone Miner Res; 2006 Feb; 21(2):283-91. PubMed ID: 16418784
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hormone replacement therapy improves distal radius bone structure by endocortical mineral deposition.
    Muller ME; Webber CE; Adachi JD
    Can J Physiol Pharmacol; 2003 Oct; 81(10):952-8. PubMed ID: 14608412
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential effects on bone density of progestogen-only methods for contraception in premenopausal women.
    Naessen T; Olsson SE; Gudmundson J
    Contraception; 1995 Jul; 52(1):35-9. PubMed ID: 8521712
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthetic progestins used in HRT have different glucocorticoid agonist properties.
    Koubovec D; Ronacher K; Stubsrud E; Louw A; Hapgood JP
    Mol Cell Endocrinol; 2005 Oct; 242(1-2):23-32. PubMed ID: 16125839
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of withdrawal of hormone replacement therapy on bone mass and bone turnover: the OFELY study.
    Sornay-Rendu E; Garnero P; Munoz F; Duboeuf F; Delmas PD
    Bone; 2003 Jul; 33(1):159-66. PubMed ID: 12919711
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Beneficial aspect of oral estriol as hormone replacement therapy: consideration on bone and lipid metabolism.
    Kika G; Izumi S; Mori A; Murano T; Suzuki T; Cai LY; Nakamura E; Goya K; Maeda H; Uchida N; Shida M
    Tokai J Exp Clin Med; 2009 Sep; 34(3):92-8. PubMed ID: 21319007
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HRT and Vit D in prevention of non-vertebral fractures in postmenopausal women; a 5 year randomized trial.
    Komulainen MH; Kröger H; Tuppurainen MT; Heikkinen AM; Alhava E; Honkanen R; Saarikoski S
    Maturitas; 1998 Nov; 31(1):45-54. PubMed ID: 10091204
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.